Accuracy of the Bayley-II mental development index at 2 years as a predictor of cognitive impairment at school age among children born extremely preterm

for the ELGAN Study Investigators

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Objective: To describe the accuracy of the Bayley Scales of Infant Development-Second Edition (BSID-II) Mental Development Index (MDI) at 2 years of age for prediction of cognitive function at school age of children born extremely preterm. Design: Study participants were enrolled in the Extremely Low Gestational Age Newborn Study between 2002 and 2004. Two-thirds of surviving children (n = 795) were assessed at 2 years with the BSID-II and at 10 years with an intelligence quotient (IQ) test. We computed test characteristics for a low MDI (<70), including predictive value positive. Results: Almost two-thirds of children with a low MDI had a normal IQ (≥ 70) at 10 years. Concordance between MDI and IQ was highest among children with major motor and/or sensory impairment, and when MDI was adjusted for gestational age. Conclusion: Most children born extremely preterm with low BSID-II MDI at 2 years have normal intelligence at school age.

Original languageEnglish (US)
Pages (from-to)908-916
Number of pages9
JournalJournal of Perinatology
Volume38
Issue number7
DOIs
StatePublished - Jul 1 2018

Funding

Acknowledgements This study was supported by the National Institute of Neurological Disorders and Stroke (Grant Nos. 5U01NS040069-05 and 2R01NS040069-09) and the Office of the Director of the National Institutes of Health (1UG3OD023348-01). We also gratefully acknowledge the contributions of their subjects, and their subjects’ families, as well as those of their colleagues listed below. This study was supported by from the Office of the Director, National Institutes of Health (1UG3OD023348-01), the National Institute of Neurological Disorders and Stroke (5U01NS040069-05 and 2R01NS040069-09), and the National Institute of Child Health and Human Development (5P30HD018655-28). Dr. Frazier has the following disclosures: serving on the data safety monitoring board for Forest Pharmaceuticals and receiving research support from Alcobra, Janssen Pharmaceuticals, Neuren, and SyneuRX International.

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Accuracy of the Bayley-II mental development index at 2 years as a predictor of cognitive impairment at school age among children born extremely preterm'. Together they form a unique fingerprint.

Cite this